PLoS One:A2DS2分数可预测中国缺血性卒中患者卒中相关肺炎和住院死亡

2016-03-14 MedSci MedSci原创

背景和目的:卒中相关性肺炎(SAP)是常见的并发症,并且也是住院期间死亡的重要原因之一。A2DS2(年龄、心房纤颤、吞咽困难、性别、卒中的严重程度)评分是柏林卒中注册开发,能够很好的预测SAP的发生。研究者旨在识别A2DS2评分和SAP之间的关联,并且确定A2DS2评分是否能预测中国人群急性缺血性卒中的死亡。方法:研究者进行了一项回顾性的研究。将1239名急性缺血性脑卒中患者分为低A2DS2组(0

背景和目的:卒中相关性肺炎(SAP)是常见的并发症,并且也是住院期间死亡的重要原因之一。A2DS2(年龄、心房纤颤、吞咽困难、性别、卒中的严重程度)评分是柏林卒中注册开发,能够很好的预测SAP的发生。研究者旨在识别A2DS2评分和SAP之间的关联,并且确定A2DS2评分是否能预测中国人群急性缺血性卒中的死亡。


方法:研究者进行了一项回顾性的研究。将1239名急性缺血性脑卒中患者分为低A2DS2组(0-4)和高A2DS2评分(5-10)组。主要预后为住院卒中相关肺炎的发生,应用Logistic回归分析确定A2DS2评分和SAP之间的关联,以及A2DS2评分和住院死亡的相关性。

结果:急性缺血性卒中后,SAP和住院死亡率的总体发生率分别为7.3%和2.4%的。低SAP组和高A2DS2评分组卒中相关性肺炎的发生率分别为3.3%和24.7%(P<0.001)。在住院期间,1.2%低评分组的患者和7.8%高分组的患者死亡。多元回归分析显示,高评分组患者卒中相关肺炎(OR 8.888, 95%CI:5.552-14.229)和死亡(OR 7.833,95% CI:3.580-17.137)的发生风险高于低评分组的患者。

结论:A2DS2评分是中国急性缺血性患者,卒中相关性肺炎和住院死亡的强预测因子。A2DS2评分可能是预测住院期间发生SAP和死亡的有效评分。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1778901, encodeId=0f681e78901ae, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Thu Apr 28 04:28:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806072, encodeId=b37d18060e278, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 30 07:28:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779277, encodeId=b1b51e7927739, content=<a href='/topic/show?id=78ef164674' target=_blank style='color:#2F92EE;'>#A2DS2分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1646, encryptionId=78ef164674, topicName=A2DS2分数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sat Oct 01 15:28:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892734, encodeId=3a8c1892e34a2, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Mar 29 04:28:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789786, encodeId=1c0c1e8978615, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Oct 31 05:28:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720101, encodeId=b5ac1e201019d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 24 16:28:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010345, encodeId=47e520103457f, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 12 08:28:00 CST 2017, time=2017-02-12, status=1, ipAttribution=)]

相关资讯

PLoS One:缺血性卒中患者,右颈动脉狭窄和认知功能相关

探讨急性缺血性脑卒中患者颈动脉狭窄与认知功能障碍的关系,并提供重要的临床意义。研究者测量了3116名急性缺血性脑卒中患者,颈动脉狭窄程度并记录简易精神状态检查评分(MMSE)。应用多变量回归分析,颈动脉狭窄与认知功能障碍(MMSE评估)的关联。也对其他感兴趣的临床变量进行了研究。在校正了年龄、性别、教育程度、婚姻、饮酒、吸烟、体力活动、高血压、糖尿病、高胆固醇血症、心房纤颤、心肌梗死、NIHSS(

J Stroke Cerebrovasc Dis:缺血性卒中患者,警惕压疮史

背景:脑卒中后的不良事件相关的因素并没有完全理解。本研究的目的是调查先前存在压疮的患者,卒中后不良事件是否增加。方法:利用台湾国家健康保险研究数据库的数据,研究者通过倾向得分匹配,进行一项回顾性队列研究。调查的2002和2009间,302名存在压疮的首发卒中患者和与3002名无压疮的卒中患者。应用多因素Logistic回归分析计算:先前存在压疮患者,卒中后,并发症和30天死亡率的校正OR值和95%

PLoS One:涉及岛叶皮质的缺血性卒中,可能是心源性栓塞的危险因素

目的:评估心源性脑栓塞是否与岛叶部位缺血性脑卒中相关。方法:识别症状开始7天内的住院的缺血性卒中患者。基于弥散加权成像,研究包括大脑中动脉(MCA)中缺血性病变。根据梗死是否涉及岛叶,将患者分为两组中一组。主要预后为根据是否涉及岛叶,比较心源性脑栓塞的频率。共有MCAO供血区发生缺血性卒中的患者,112名(8.5%)涉及到岛叶。与未涉及岛叶(30.4%)的患者相比,涉及岛叶卒中(52.7%)的患者

Stroke:急性使用可卡因增加了早发性缺血性脑卒中的风险

虽然病例报告早就确定了使用可卡因和缺血性脑卒中(IS)之间的关联,但很少有流行病学研究阐述青壮年IS与使用可卡因的关联,通过定期的,途径和使用频率进行确定。研究人员进行了一项基于人群的病例对照研究,通过1090例患者和1154名对照来调查使用可卡因和青年人IS发病的关联。卒中病例均在15至49岁之间。采用Logistic回归分析,以评估使用可卡因和IS之间的关联,其中的IS是经过了有或没有潜在的混

NEJM:吡格列酮治疗缺血性卒中或短暂性脑缺血发作效果一般

尽管使用当前的预防性疗法,缺血性中风或短暂性脑缺血发作(TIA)患者的未来心血管事件的风险增加。胰岛素抗性的识别作为中风和心肌梗塞的危险因素,提高了吡格列酮治疗的可能性,改善了胰岛素的敏感性,可能增加脑血管疾病的患者受益的可能性。在这个多中心,双盲试验中,研究人员随机分配3876例近期患缺血性卒中或TIA的患者分别接受吡格列酮(目标剂量,每天45毫克)或安慰剂。符合条件的患者没有糖尿病,但被发现在

Stroke:DASH饮食可降低缺血性卒中风险

坚持饮食疗法停止高血压(DASH)饮食可降低高血压的风险,高血压是脑卒中的主要危险因素。研究人员探讨了是否坚持DASH饮食可降低卒中的发病率。研究人群包括74404名男性和女性(45-83岁),基线时无卒中,这些参与者来自瑞典男性的队列和瑞典乳房X光摄影队列。饮食通过饮食频率问卷评估。一种改进的DASH饮食评分是基于对蔬菜,水果,豆类和坚果,全谷类,低脂奶制品,红肉和加工肉类和含糖饮料消费的产生的